DIO2 and neoplasm: To evaluate tumor progression in an epidermal-specific D2KO background (sD2KO), we depleted D2 from the epidermal compartment by administrating tamoxifen before the DMBA/TPA treatment and analyzed the skin lesions 20 weeks later (Fig. 3a).